Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B

In 2010, nonacog alfa became the first recombinant factor IX (rFIX) available in Japan for patients with haemophilia B.

[1]  L. Graf.  Extended Half-Life Factor VIII and Factor IX Preparations , 2018, Transfusion Medicine and Hemotherapy.

[2]  F. Peyvandi,et al.  First‐year results of an expanded humanitarian aid programme for haemophilia in resource‐constrained countries , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Puetz,et al.  Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  P. Monahan,et al.  Safety and efficacy of investigator‐prescribed BeneFIX® prophylaxis in children less than 6 years of age with severe haemophilia B , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[7]  C. Kessler.  New perspectives in hemophilia treatment. , 2005, Hematology. American Society of Hematology. Education Program.

[8]  M. Manco‐Johnson.  Update on treatment regimens: prophylaxis versus on-demand therapy. , 2003, Seminars in hematology.

[9]  J. Katz.  Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large‐scale North American survey , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.